Cell and gene therapy developers face persistent challenges in media and buffer preparation, ranging from variability and scalability to cost and operational complexity. In this webinar, Nucleus Biologics introduces the Krakatoa® K500, the first bioreactor-scale, pod-based manufacturing system enabling on-demand, co-located media and buffer production. Learn how this innovation improves consistency, traceability, and operational efficiency while accelerating advanced therapy manufacturing timelines.
Visit our product page to learn more about Krakatoa K500.